Title : MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells.

Pub. Date : 2019 Dec

PMID : 31691527






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In addition, erlotinib, a US Food and Drug Administration approved cancer drug which targets EGFR, was able to rescue MYST1-promoted cell proliferation and EGFR signaling pathway. erlotinib lysine acetyltransferase 8 Homo sapiens